Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine

Journal of Infectious Diseases

Volumn 200, Issue 4, 2009, Pages 501-509

  Beigel, John H ^a   Voell, Jocelyn ^a   Huang, Chiung Yu ^a   Burbelo, Peter D ^b   Clifford Lane, H ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA A/H5N1 VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ABDOMINAL PAIN; ADULT; ALLERGIC RHINITIS; ANEMIA; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FASCICULATION; FATIGUE; FEMALE; FEVER; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H5N1; LYMPHADENITIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MOUTH ULCER; MYALGIA; NAUSEA; PRIORITY JOURNAL; RHINITIS; SERUM; SKIN DISEASE; SLEEP DISORDER; SORE THROAT; STATISTICAL SIGNIFICANCE; TASTE DISORDER; VACCINATION; VOMITING; ADOLESCENT; BLOOD; DOSE RESPONSE; HEMAGGLUTINATION TEST; IMMUNOLOGY; MIDDLE AGED; SERODIAGNOSIS; TIME;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEMAGGLUTINATION TESTS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; TIME FACTORS; YOUNG ADULT;

EID: 69149086060     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/599992     Document Type: Article

References (20)

1. Knobler SL, Mack A, Mahmoud A, Lemon SM, eds. The threat of pandemic influenza: are we ready? Workshop summary prepared for Forum on Microbial Threats, Board on Global Health. Washington, DC: National Academies Press, 2005.
2. He G, Qiao J, Dong C, He C, Zhao L, Tian Y. Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral Res 2008; 77:72-76
3. Cheung CL, Rayner JM, Smith GJ, et al. Distribution of amantadineresistant H5N1 avian influenza variants in Asia. J Infect Dis 2006; 193: 1626-1629
4. 4. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353: 2667-2672 (Pubitemid 41817715)
5. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis 2007;13:1354-1357
6. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145:599-609.
7. 7. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007;357:1450-1451 (Pubitemid 47535608)
8. 8.OkunoY,MatsumotoK,IsegawaY,UedaS.Protectionagainstthemouse-adaptedA/FM/ 1/47strainofinfluenzaAvirusinmicebyamonoclonalantibodywithcross- neutralizingactivityamongH1andH2strains.JVirol1994;68:517-520(Pubitemid24974658)
9. 2 in mice. Respir Res 2006; 7:43.
10. 10. Mozdzanowska K, Feng J, Eid M, Zharikova D, Gerhard W Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology 2006;352:418-426 (Pubitemid 44216008)
11. Palladino G, Mozdzanowska K, Washko G, Gerhard W Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 1995;69:2075-2081
12. 12. Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, Webby RJ. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 2006; 7:126. (Pubitemid 44642593)
13. Simmons CP, Bemasconi NL, Suguitan AL, et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007; 4:e 178.
14. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354:1343-1351
15. Keitel WA, Couch RB, Cate TR, et al. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol 1994; 32: 2468-2473
16. Burbelo PD, Meoli E, Leahy HP, et al. Anti-HTLV antibody profiling reveals an antibody signature for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology 2008; 5:96.
17. 17. Burbelo PD, Goldman R, Mattson TL. A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferaseantigen fusion proteins. BMC Biotechnol 2005; 5:22. (Pubitemid 41461010)
18. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-130
19. 19. Zangwill KM, Treanor JJ, Campbell JD, Noah DL, Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 2008; 197: 580-583 (Pubitemid 351321536)
20. Shaw FE Jr, Guess HA, Roets JM, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989; 7:425-430